H.R. 4640 · 116th Congress
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
DeFazioSponsor11 cosponsors · 11 D
D
Doggett
RK
D
Khanna
PW
D
Welch
MP
D
Pocan
JS
D
Schakowsky
RD
D
DeLauro
RG
D
Grijalva
SC
D
Cohen
MK
D
Kaptur
CP
D
Pingree
CG
D
García0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019
What it does: CRS summary · Introduced in House · Oct 11, 2019
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019
This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019
Latest action (Oct 14, 2019): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Oct 11, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.